Dr. Yu on the Future of Castration-Sensitive Prostate Cancer

Video

Evan Y. Yu, MD, professor, Department of Medicine, Division of Oncology, University of Washington, Seattle Cancer Care Alliance, discusses the future of castration-sensitive prostate cancer.

Evan Y. Yu, MD, professor, Department of Medicine, Division of Oncology, University of Washington, Seattle Cancer Care Alliance, discusses the future of castration-sensitive prostate cancer.

Treatment for castration-sensitive disease has garnered a lot of excitement, says Yu. When it comes to treating patients with castration-sensitive disease, the challenge is clinical trial development. This is a good challenge to have, explains Yu, because the prognosis is good—these patients live for years. Because of that, it takes a long time for the data to mature.

The more immediate developments that are being made in the field are the use of immunotherapy agents such as PD-1/PD-L1 antibodies, as well as patient selection for those agents. The introduction of PARP inhibitors for homologous recombination-deficient patients has also received a lot of press.

Physicians have yet to work out if combining immunotherapy agents with PARP inhibitors is a viable strategy moving forward, notes Yu. However, he states that these approaches are all being tested in patients with metastatic castration-resistant prostate cancer, and physicians are likely to receive an answer soon.

Related Videos
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD
Minesh Mehta, MD
Ruben Olivares, MD
Phillip J. Koo, MD